REGENXBIO Inc. (NASDAQ:RGNX – Get Rating) CFO Vittal Vasista sold 4,332 shares of the stock in a transaction dated Wednesday, July 13th. The stock was sold at an average price of $30.01, for a total transaction of $130,003.32. Following the completion of the transaction, the chief financial officer now directly owns 158,108 shares of the company’s stock, valued at approximately $4,744,821.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
REGENXBIO Trading Up 3.8 %
NASDAQ RGNX traded up $1.17 during mid-day trading on Friday, hitting $31.58. The company’s stock had a trading volume of 15,360 shares, compared to its average volume of 462,788. The company’s 50 day simple moving average is $22.88 and its 200 day simple moving average is $26.69. REGENXBIO Inc. has a twelve month low of $18.69 and a twelve month high of $46.46. The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of 14.41 and a beta of 0.97.
REGENXBIO (NASDAQ:RGNX – Get Rating) last posted its quarterly earnings results on Wednesday, May 4th. The biotechnology company reported ($1.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.29) by ($0.33). REGENXBIO had a net margin of 21.38% and a return on equity of 17.92%. The business had revenue of $22.22 million during the quarter, compared to analyst estimates of $28.13 million. As a group, research analysts forecast that REGENXBIO Inc. will post -5.06 EPS for the current year.
Wall Street Analyst Weigh In
Ad Investing Trends
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium
The soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It’s lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.
A number of research firms have recently commented on RGNX. TheStreet cut shares of REGENXBIO from a “c” rating to a “d+” rating in a report on Monday, May 16th. Wedbush reiterated a “hold” rating and issued a $29.00 price objective on shares of REGENXBIO in a report on Monday. Morgan Stanley dropped their price objective on shares of REGENXBIO from $51.00 to $47.00 and set an “overweight” rating for the company in a report on Tuesday, May 24th. UBS Group dropped their price objective on shares of REGENXBIO from $51.00 to $47.00 and set a “buy” rating for the company in a report on Thursday, June 23rd. Finally, Berenberg Bank assumed coverage on shares of REGENXBIO in a report on Thursday, June 23rd. They issued a “buy” rating and a $61.00 price objective for the company. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $48.78.
Institutional Trading of REGENXBIO
Several hedge funds have recently bought and sold shares of RGNX. Sofinnova Investments Inc. grew its position in REGENXBIO by 690.1% in the 4th quarter. Sofinnova Investments Inc. now owns 1,008,081 shares of the biotechnology company’s stock valued at $32,964,000 after purchasing an additional 880,488 shares during the period. JPMorgan Chase & Co. lifted its stake in REGENXBIO by 20.9% during the 4th quarter. JPMorgan Chase & Co. now owns 5,004,773 shares of the biotechnology company’s stock valued at $163,656,000 after acquiring an additional 864,447 shares in the last quarter. WS Management Lllp lifted its stake in REGENXBIO by 66.2% during the 1st quarter. WS Management Lllp now owns 474,300 shares of the biotechnology company’s stock valued at $15,742,000 after acquiring an additional 189,000 shares in the last quarter. State Street Corp lifted its stake in REGENXBIO by 6.6% during the 1st quarter. State Street Corp now owns 2,653,766 shares of the biotechnology company’s stock valued at $88,078,000 after acquiring an additional 163,513 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in REGENXBIO by 101.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 277,700 shares of the biotechnology company’s stock valued at $9,081,000 after acquiring an additional 139,947 shares in the last quarter. Institutional investors and hedge funds own 87.57% of the company’s stock.
About REGENXBIO
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should you invest $1,000 in REGENXBIO right now?
Before you consider REGENXBIO, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and REGENXBIO wasn’t on the list.
While REGENXBIO currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: REGENXBIO Inc. (NASDAQ:RGNX) CFO Sells $130,003.32 in Stock